Dear Authors,
If you believe that your paper was mistakenly rejected by other leading journals and you do not agree with final decision, the editors of Reports of Practical Oncology and Radiotherapy offer new fast track review. You may submit your manuscript to Reports of Practical Oncology and Radiotherapy together with all prior peer-reviews obtained from the other journal and your rebuttal letter. We guarantee review based decision within 72 hours from the time we will receive your manuscript.

Fast track submission process: Please submit the manuscript with all reviews and rebuttal letter by email to Dr. Michal Masternak (michal.masternak@ucf.edu) for fast review processing. To assure immediate attention the email title must to include: RPOR-fast track- Last Name First Name (of corresponding author).

Volume 11, Number 5, 2006

PSA bounces after brachytherapy HDR and external beamradiation therapy for prostate cancer

Roman Makarewicz, Krzysztof Roszkowski, Andrzej Lebioda, Joanna Reszke, Ewa Ziółkowska

Summary:

Background The serum prostate-specifi c antigen (PSA) test is the most commonly used method for confirming response of prostate cancer after defi nitive radiation therapy (RT). PSA levels are expected to decrease after radiotherapy but usually remain detectable. Three consecutive PSA rises above the post-treatment nadir have been defined as biochemical failure by the ASTRO consensus panel [1]. Rising serum PSA concentration after RT does not always indicate treatment failure. Some patients have a temporary PSA spike, usually within 12–30 months of radiation therapy [2–4]. Most PSA bounces have a magnitude of 1.0ng/mL or less. This observation was first described by Wallner and colleagues in 1997 [5]. Although this phenomenon is a source of anxiety for both the patient and the physician, its relevance to biochemical failure is controversial.
Aim To determine the clinical and dosimetric factors that predict prostate-specifi c antigen (PSA) bouncing following brachytherapy HDR and three-dimensional conformal radiation therapy (3D-CRT) for prostate cancer patients.
Materials/Methods The evaluated population consisted of 71 hormone-naive patients with a minimum of 2 years of follow-up and at least 6 post-treatment PSA levels. All patients were treated using 3D-CRT combined with brachytherapy HDR. A bounce was defined as a PSA rise of ≥0.2ng/mL above the nadir followed by a subsequent 120 decline of ≥0.2ng/mL. Clinical factors evaluated included: patient age, Gleason score, maximum initial pretreatment PSA value (iPSAmax), clinical stage, prostate volume, median time to PSA nadir, median PSA nadir value and patient follow-up in months. Dosimetric factors evaluated included the percentage of the prostate volume receiving 100% (V100), 150% (V150) and 200% (V200) of the prescribed minimal peripheral dose.
Results Statistically significant predictive factors for PSA bounce were age, V100, V150, V200, iPSAmax and median time to PSA nadir. Logistic regression model for multivariate analysis revealed that only age, iPSAmax and V200 were statistically significant predictors for PSA bounce. There were no statistical differences between median nadir among patients who exhibited a PSA bounce and those who did not, but non-bouncers reached PSA nadir earlier than bouncers; median time was 12.1 vs 17.2 months respectively.
Conclusion PSA bouncing occurs in approximately one third (1/3) of patients treated with 3D-CRT and brachytherapy HDR. Bouncing is associated with age, higher pretreatment PSA level and increased V200 factor.

Signature: Rep Pract Oncol Radiother, 2006; 11(5) : 217-222

FULL TXT (PDF: 0,09MB)

« back

 
INDEXED IN:

Indexed in: EMBASE®, the Excerpta Medica database, the Elsevier BIOBASE (Current Awareness in Biological Sciences) and in the Index Copernicus.

http://www.sciencedirect.com/science/journal/15071367/19/2